Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax stock popped Wednesday after the small biotech company said it plans to begin human testing of its coronavirus vaccine in mid-May.

Covid Report: Small Biotech Surges On Plan To Test Vaccine In May

Its coronavirus program is moving along at warp speed.

Why Novavax Stock (NVAX) Is Jumping Today

Novavax, Inc. (NASDAQ: NVAX), which has been working on a vaccine to treat the new coronavirus that causes COVID-19, announced Wednesday that it has identified a candidate, NVX-CoV2373.

Novavax Identifies COVID-19 Vaccine Candidate, Human Testing To Begin In Mid-May

Shares of Novavax Inc. NVAX, -7.45% jumped 9% in premarket trading on Wednesday after the company said it had identified a COVID-19 vaccine candidate.

Novavax to start Phase 1 trials for COVID-19 vaccine next month

GAITHERSBURG, Md., April  08, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.

Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May

Regeneron Pharmaceuticals

Both of these biotechs have promising coronavirus programs. But which is the better pick overall?

Better Coronavirus Stock: Novavax vs. Regeneron

Novavax (NVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Novavax (NVAX): Strong Industry, Solid Earnings Estimate Revisions

Johnson & Johnson

Moderna

Sanofi

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

Novavax's flu vaccine could be a game-changer for the company.

Novavax Stock Could Easily Triple in Value

This high-flying biotech stock could stumble. But it could also fly even higher.

Should You Buy Novavax Stock Right Now?

Investors began buying up NVAX shares in anticipation of the Phase 3 clinical trial announcement. We wound up with a 130% gain on the trade.

How We “Flipped” a Beaten-Down Company for 126% Gains

A rising stock market and continued excitement over last week's positive clinical results lifted the biotech higher.

Why Novavax Stock Jumped Nearly 10% Today

Co-Diagnostics

Trillium Therapeutics

These stocks have soared while the overall market tanked. But are they buys?

The 3 Most Resilient Stocks in the Bear Market Today

Roku

Vaxart

Zoom Video

Unlike the broader market, these stocks to buy have managed to hold up strong amid the ongoing public health crisis.

5 Stocks to Buy That Are Holding Strong While Everything Else Crumbles

Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.

Novavax Rallies as Influenza Vaccine Meets All Goals in Study

After the biotech company needed a 1-for-20 reverse stock split last year to avoid being delisted, Novavax has hit a home run with NanoFlu.

Novavax Gets a Big Win for Its Flu Vaccine in Phase 3 Trial

Novavax, Inc. (NASDAQ: NVAX), which was in the news recently on account of its COVID-19 vaccine development program, is in the spotlight yet again Tuesday.

Novavax Shares Rally On Flu Vaccine Study Results: What You Need To Know

Shares of Novavax Inc. NVAX, +3.96% rocketed 37% in premarket trading Tuesday, after the biotechnology company said its NanoFlu treatment for seasonal flu achieved all primary endpoints in a phase 3 trial for adults 65 an older.

Novavax's stock rockets after late-stage trial for flu treatment achieves primary endpoints

Bicycle Therapeutics Plc - ADR

Catalyst Pharmaceuticals

Amicus Therapeutics

Inovio Pharmaceuticals

These five biotech stocks could post life-changing gains for early-bird investors.

5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich

Cogent Communications Holdings

Clorox

Campbell Soup

The current volatility in equity market calls for investment in these five low-beta stocks.

5 Low-Beta Stocks to Tackle Coronavirus-Led Market Volatility

Investors appear to be anticipating good news for the biotech.

Why Novavax Stock Jumped Today While the Market Crashed

Arcturus Therapeutics

Aurinia Pharmaceuticals

Chemocentryx

Kadmon Hlds

Nevro

Thermo Fisher Scientific

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

7 “Perfect 10” Healthcare Stocks to Buy Now

Shares of Moderna  soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19

Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys

While the spread of COVID-19 has destroyed billions of dollars of market value, stocks in healthcare companies that are fighting the virus continue to advance.

2 Winning Stocks to Buy in the Coronavirus Panic

MannKind

An overall market rebound and some company-specific news are lighting a fire beneath these stocks.

News for Novavax Stock (NVAX)